Showing 541 - 560 results of 135,661 for search '(( 2 we decrease ) OR ( 5 ((((we decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 1.86s Refine Results
  1. 541
  2. 542

    Ligand-Controlled Magnetic Interactions in Mn<sub>4</sub> Clusters by Erik Kampert (2330428)

    Published 2009
    “…Experimentally measured magnetic moments in high magnetic fields show that, upon electron density withdrawal, the main antiferromagnetic exchange constant <i>J</i><sub>1</sub> decreases from −2.2 K for the [Mn<sub>4</sub>(OAc)<sub>4</sub>] cluster to −1.9 K for the [Mn<sub>4</sub>(H<sub>5</sub>C<sub>6</sub>COO)<sub>4</sub>] cluster and −0.6 K for the [Mn<sub>4</sub>(F<sub>3</sub>CCOO)<sub>4</sub>] cluster, while <i>J</i><sub>2</sub> decreases from −1.1 K to nearly 0 K and <i>J</i><sub>3</sub> changes to a small ferromagnetic coupling. …”
  3. 543

    Ligand-Controlled Magnetic Interactions in Mn<sub>4</sub> Clusters by Erik Kampert (2330428)

    Published 2009
    “…Experimentally measured magnetic moments in high magnetic fields show that, upon electron density withdrawal, the main antiferromagnetic exchange constant <i>J</i><sub>1</sub> decreases from −2.2 K for the [Mn<sub>4</sub>(OAc)<sub>4</sub>] cluster to −1.9 K for the [Mn<sub>4</sub>(H<sub>5</sub>C<sub>6</sub>COO)<sub>4</sub>] cluster and −0.6 K for the [Mn<sub>4</sub>(F<sub>3</sub>CCOO)<sub>4</sub>] cluster, while <i>J</i><sub>2</sub> decreases from −1.1 K to nearly 0 K and <i>J</i><sub>3</sub> changes to a small ferromagnetic coupling. …”
  4. 544
  5. 545

    <i>B-MOBILE</i> - A Smartphone-Based Intervention to Reduce Sedentary Time in Overweight/Obese Individuals: A Within-Subjects Experimental Trial by Dale S. Bond (588506)

    Published 2014
    “…Average % SED at baseline (72.2%) decreased by 5.9%, 5.6%, and 3.3% [i.e. by mean (95% CI) −47.2(−66.3, −28.2), −44.5(−65.2, −23.8), and −26.2(−40.7, −11.6) min/d] in the 3-, 6-, and 12-min conditions, respectively. …”
  6. 546
  7. 547

    Overview of study procedures. by Matthew G. Vinson (22593374)

    Published 2025
    “…VIDEO and CONTROL were associated with a similar rise in intent to decrease OTC NSAID use (1.92 (SD: 4.41) vs. 1.36 (SD: 3.46), p = 0.150) and a similar decrease in NSAIDs exposure (−32.8% in VIDEO and −36.5% in CONTROL, p = 0.520) 4 weeks post-intervention. …”
  8. 548

    Image_1_Artesunate Alleviates Paclitaxel-Induced Neuropathic Pain in Mice by Decreasing Metabotropic Glutamate Receptor 5 Activity and Neuroinflammation in Primary Sensory Neurons.... by Yize Li (471459)

    Published 2022
    “…Artesunate normalized paclitaxel-related expression changes in DRG mGluR5, NR1, and GluA2, as well as six paclitaxel related neuroinflammation markers. …”
  9. 549
  10. 550

    Supplementary Material for: Optimistic Youth: Young Adults Predicted a Faster Decrease in Risk during COVID-19 Emergency State in Portugal by Scaletti S. (12434691)

    Published 2022
    “…‘in two weeks’ time’, or ‘in four weeks’ time’) of both risk behaviour and importance of transmission prevention decrease over time. …”
  11. 551
  12. 552

    Heterologous Immunity Triggered by a Single, Latent Virus in <i>Mus musculus</i>: Combined Costimulation- and Adhesion- Blockade Decrease Rejection by Jonathan M. Beus (441623)

    Published 2013
    “…MHV68 infection was correlated with multimodal immune deviation, which included increased secretion of CXCL9 and CXCL10, and with the expansion of a CD8<sup>dim</sup> T cell population. CD8<sup>dim</sup> T cells exhibited decreased expression of multiple costimulation molecules and increased expression of two adhesion molecules, LFA-1 and VLA-4. …”
  13. 553
  14. 554
  15. 555
  16. 556
  17. 557
  18. 558

    A PPARα Promoter Variant Impairs ERR-Dependent Transactivation and Decreases Mortality after Acute Coronary Ischemia in Patients with Diabetes by Sharon Cresci (53599)

    Published 2010
    “…Consistent with previous descriptions of PPARα in experimental models and human disease, we describe a novel <em>PPARA</em> promoter SNP that decreases transcriptional activation of <em>PPARA</em> and protects against mortality in diabetic patients after ACS.…”
  19. 559
  20. 560